⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
VSTM News
Verastem, Inc.
Verastem Oncology to Report Third Quarter 2026 Financial Results on November 5, 2026
businesswire.com
VSTM
Form 8-K
sec.gov
PDSB
BMY
GTBP
VSTM
Form 8-K
sec.gov
VSTM
Form 8-K
sec.gov
VSTM
Verastem Oncology Announces Planned Chief Executive Officer Transition and Succession Plan
businesswire.com
VSTM
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
businesswire.com
VSTM
Verastem Oncology Announces New RAMP 201 Molecular Profiling and External Control Arm Analyses Describing Outcomes for Avutometinib Plus Defactinib in Recurrent Low-Grade Serous Ovarian Cancer to be Presented at IGCS 2026
businesswire.com
VSTM
KRAS Inhibitor Market Projected to Reach $7.8 Billion by 2034
prnewswire.com
LLY
RVMD
ONCY
AMGN
VSTM
Verastem Oncology to Unveil New Clinical Data Highlighting the Best-in-Class Potential of VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, Across Pancreatic, Lung, and Colorectal Cancers
businesswire.com
VSTM
Form 8-K
sec.gov
VSTM